Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years

Siponimod significantly reduced the risk of confirmed disability progression (CDP), worsening in cognitive processing speed (CPS), relapses, and magnetic resonance imaging (MRI) measures of brain atrophy and inflammation versus placebo in secondary progressive multiple sclerosis (SPMS) patients in t...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Multiple sclerosis Jg. 28; H. 10; S. 1591
Hauptverfasser:	Cree, Bruce Ac, Arnold, Douglas L, Fox, Robert J, Gold, Ralf, Vermersch, Patrick, Benedict, Ralph Hb, Bar-Or, Amit, Piani-Meier, Daniela, Rouyrre, Nicolas, Ritter, Shannon, Kilaru, Ajay, Karlsson, Goeril, Giovannoni, Gavin, Kappos, Ludwig
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England 01.09.2022
Schlagworte:	Atrophy Azetidines Benzyl Compounds Humans Multiple Sclerosis - drug therapy Multiple Sclerosis, Chronic Progressive - drug therapy Multiple Sclerosis, Relapsing-Remitting - drug therapy Recurrence confirmed cognitive worsening cortical gray matter S1P modulator secondary progressive multiple sclerosis Confirmed disability progression siponimod
ISSN:	1477-0970, 1477-0970
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!